Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Short term Debt (2017 - 2026)

Avanos Medical's Short term Debt history spans 8 years, with the latest figure at $10.2 million for Q4 2025.

  • On a quarterly basis, Short term Debt rose 8.51% to $10.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.2 million, a 8.51% increase, with the full-year FY2025 number at $10.2 million, up 8.51% from a year prior.
  • Short term Debt hit $10.2 million in Q4 2025 for Avanos Medical, up from $9.4 million in the prior quarter.
  • Over the last five years, Short term Debt for AVNS hit a ceiling of $10.2 million in Q2 2024 and a floor of $4.7 million in Q2 2022.
  • Historically, Short term Debt has averaged $8.1 million across 4 years, with a median of $9.4 million in 2024.
  • Biggest five-year swings in Short term Debt: skyrocketed 64.52% in 2024 and later dropped 7.84% in 2025.
  • Tracing AVNS's Short term Debt over 4 years: stood at $6.2 million in 2022, then surged by 38.71% to $8.6 million in 2023, then rose by 9.3% to $9.4 million in 2024, then rose by 8.51% to $10.2 million in 2025.
  • Business Quant data shows Short term Debt for AVNS at $10.2 million in Q4 2025, $9.4 million in Q3 2025, and $9.4 million in Q2 2025.